AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00058214
Drug: perifosine
RxNorm normalized name: Perifosine
DrugBank: Perifosine (DB06641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02191007
Drug: Calcipotriol Betamethasone ointment and Calcipotriol ointment
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02191007
Drug: Calcipotriol Betamethasone ointment
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02443545
Drug: Deferiprone
RxNorm normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02401477
Drug: Ilaprazole + Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ilaprazole 40mg BID, dosage form : delayed release tablet Amoxicillin 750mg QID, dosage form : capsule
Trial: NCT01397708
Drug: INXN-1001
RxNorm normalized name: DNA (RECOMBINANT LENTIVIRUS VECTOR INXN-2004-TRANSDUCED HUMAN AUTOLOGOUS DYSTROPHIC EPIDERMOLYSIS BULLOSA DERMAL FIBROBLAST CELL FCX-007 INTEGRATED PROVIRAL HUMAN COLLAGEN TYPE VII TRANSGENE COL7A1 PLUS 5'-HUMAN CYTOMEGALOVIRUS PROMOTER/UTR-AND 3'-LTR/PO
DrugBank: Dabocemagene autoficel (DB17878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * 4 dose cohorts (5mg/day, 20mg/day, 100mg/day, and 160mg/day)~* 7 oral daily doses of INXN-1001 per study cycle~* maximum of 6 study cycles~* 1 Expansion cohort at a single dose level at or below MTD (160mg/day)
Trial: NCT03808870
Drug: NBM-BMX softgel capsules
RxNorm normalized name: docusate sodium Oral Capsule [Correctol Softgel Extra Gentle]
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will initially receive NBM-BMX orally once a day at 100 mg per day.
Trial: NCT00402220
Drug: TMS
RxNorm normalized name: TMTMS
DrugBank: Tetramethylthiuram monosulfide (DB14178)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Transcranial Magnetic Stimulation
Trial: NCT00788229
Drug: AT01
RxNorm normalized name: MaaT013
DrugBank: MaaT013 (DB18648)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eye drop for 12 weeks
Trial: NCT00788229
Drug: AT02
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: eye drop for 12 weeks
Trial: NCT00788229
Drug: AT03
RxNorm normalized name: KARAYA GUM WASHER,TORBOT #AT0312
DrugBank: Karaya gum (DB10535)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eye drop for 12 weeks
Trial: NCT00788229
Drug: AT04
RxNorm normalized name: Azelastine hydrochloride
DrugBank: Azelastine (DB00972)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: eye drop for 12 weeks
Trial: NCT00052026
Drug: carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: low-dose carvedilol administered twice daily for 8 months
Trial: NCT00052026
Drug: carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: high-dose carvedilol administered twice daily for 8 months
Trial: NCT02516423
Drug: ixazomib
RxNorm normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral
Trial: NCT02516423
Drug: lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral
Trial: NCT02516423
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral
Trial: NCT03794518
Drug: Pioglitazone Plus dapaglifliozin
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone Plus dapaglifliozin
Trial: NCT02761213
Drug: Oral sulfate solution (OSS)
RxNorm normalized name: Oral Film
DrugBank: Citric acid (DB04272)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sulfate solution (OSS)
Trial: NCT00531349
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: General anesthesia
Trial: NCT00478569
Drug: Parathyroid Hormone (PTH) (1-84)
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adherence to PTH(1-84) treatment in Usual Clinical Settings
Trial: NCT03407521
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: induction of abortion using misoprostol
Trial: NCT03407521
Drug: isosorbide mononitrate
RxNorm normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: isosorbide mononitrate
Trial: NCT02664441
Drug: Exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly injections of active drug.
Trial: NCT00353561
Drug: Boric
RxNorm normalized name: Boric Acid
DrugBank: Boric acid (DB11326)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gelatin capsules filled with 600 mg of boric acid
Trial: NCT01758146
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg once daily for 5 years
Trial: NCT01758146
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letroz, Femara, Letronat
Trial: NCT04365179
Drug: Nerofe
RxNorm normalized name: Nerofe
DrugBank: Nerofe (DB14786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 12 cycles of 28 days are planned. If patients are deriving benefit, treatment may continue past 12 cycles.~Cycle 1: During Cycle 1, assigned NEROFE doses will be administered by intravenous (IV) infusion over 1 hour on Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26.~Cycles 2-12: Subsequent cycles will be administered as above, presuming that patients do not meet criteria for study withdrawal during cycle 1.
Trial: NCT03351231
Drug: BMS-986242
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT00655278
Drug: T2000
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: T2000 at previous most effective, well-tolerated dose (600-1000mg daily)
Trial: NCT00236249
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00093002
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 250 mg \& 500 mg intramuscular injection
Trial: NCT03499119
Drug: AMG 334 Dose 1
RxNorm normalized name: AMG-222
DrugBank: AMG-222 (DB06011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 3.~Subjects weighing weight threshold or more at Day 1 will be randomized to either Dose 1 or Dose 2
Trial: NCT03499119
Drug: AMG 334 Dose 2
RxNorm normalized name: AMG-222
DrugBank: AMG-222 (DB06011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects weighing weight threshold or more at Day 1 will be randomized to either Dose 1 or Dose 2.
Trial: NCT03499119
Drug: AMG 334 Dose 3
RxNorm normalized name: AMG-222
DrugBank: AMG-222 (DB06011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 3.
Trial: NCT00353561
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg oral fluconazole gives once in 14 days
Trial: NCT01486914
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single dose of each formulation administrated subcutaneously (s.c., under the skin) at two separate dosing visits
Trial: NCT02336620
Drug: Ringer acetate
DrugBank: COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection (DB15845)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer acetate 10-20 ml/kg IV bolus in 15-30 min,repeat bolus as needed by patient status
Trial: NCT01876849
Drug: exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, 5mcg or 10 mcg, twice daily
Trial: NCT03365999
Drug: Oral Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients undergoing total knee replacement who will receive three doses of tranexamic acid administered orally (1 prior to surgery and 2 subsequent to surgery).
Trial: NCT03365999
Drug: Oral Aminocaproic Acid
RxNorm normalized name: Aminocaproic Acid
DrugBank: Aminocaproic acid (DB00513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients undergoing total knee replacement who will receive three doses of aminocaproic acid administered orally (1 prior to surgery and 2 subsequent to surgery).
Trial: NCT02333487
Drug: Lu AF35700
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg tablets for oral administration
Trial: NCT00027508
Drug: trabectedin
RxNorm normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00101413
Drug: Sorafenib (Nexavar, BAY43-9006)
RxNorm normalized name: sorafenib 200 MG [Nexavar]
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BAY43-9006 400 mg bid X 28 day cycles \[Continuous treatment for a maximum of 2 years; potential for compassionate use and long term survival follow-up post drug discontinuation.
Trial: NCT00864617
Drug: Nifedipine Extended Release tablets 60 mg, single dose
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A: Experimental Subjects received Abrica Pharmaceuticals LLLP formulated products under non-fasting conditions
Trial: NCT02758249
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients are anesthetized by using sevoflurane inhalation
Trial: NCT02758249
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients are anesthetized by using propofol infusion
Trial: NCT03235869
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab 1500mg IV over 1 hour administered within 2-7 days of initiation of radiation, then every 28 days.
Trial: NCT06440187
Drug: Gemcitabine+ nivolumab
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine+ nivolumab q 2wks
Trial: NCT00131755
Drug: diazoxide
RxNorm normalized name: Diazoxide
DrugBank: Diazoxide (DB01119)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00093951
Drug: SGS742
RxNorm normalized name: SGS742
DrugBank: SGS-742 (DB05010)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03627741
Drug: Triamcinolone Acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A concentration of 40 mg/ml of Triamcinolone Acetonide will be used for injections with a total dose of 120 mg of Triamcinolone given per injection. The injections will be performed under ultrasound guidance by a fellowship-trained musculoskeletal radiologist. The injection locations will be left to the discretion of the radiologist with the request to attempt to distribute the drug throughout the tumor. A total of three injections will be performed at six week intervals.
Trial: NCT00667082
Drug: NPI-0052 (marizomib) + vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NPI-0052 IV injection over 1 to 10 minutes at doses ranging from 0.15 to 0.7 mg/m2 on Days 1, 8, and 15 of each 28-day Cycle~Oral vorinostat 300 mg was administered with food on Days 1 to 16 of each 28-day Cycle
Trial: NCT02946684
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy to recFSH during ovarian stimulation
Trial: NCT02470117
Drug: magnesium-aluminium antacid gel
RxNorm normalized name: Magnesium aluminium silicate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03380520
Drug: Ferric Carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose will be administered according to product specification dosing
Trial: NCT02322788
Drug: Terbutaline sulphate
RxNorm normalized name: Terbutaline sulphate
DrugBank: Terbutaline (DB00871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bricanyl Turbuhaler M2
Trial: NCT02322788
Drug: Terbutaline sulphate
RxNorm normalized name: Terbutaline sulphate
DrugBank: Terbutaline (DB00871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bricanyl Turbuhaler M3
Trial: NCT02322788
Drug: Placebo for terbutaline sulphate
DrugBank: Terbutaline (DB00871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo Turbuhaler M2
Trial: NCT02322788
Drug: Placebo for terbutaline sulphate
DrugBank: Terbutaline (DB00871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo Turbuhaler M3
Trial: NCT01014416
Drug: Tolvaptan 15mg or 30mg or 60mg or Placebo
RxNorm normalized name: edaravone
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single dose of Tolvaptan 15mg or 30mg or 60mg or Placebo per day
Trial: NCT00388895
Drug: Glivec
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00107718
Drug: SB-485232
RxNorm normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02477852
Drug: Isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: preoperative treatment of spinal tuberculosis with Isoniazid
Trial: NCT02477852
Drug: Rifampicin
RxNorm normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: preoperative treatment of spinal tuberculosis with Rifampicin
Trial: NCT02477852
Drug: Ethambutol
RxNorm normalized name: Ethambutol
DrugBank: Ethambutol (DB00330)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: preoperative treatment of spinal tuberculosis with Ethambutol
Trial: NCT02477852
Drug: Pyrazinamide
RxNorm normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: preoperative treatment of spinal tuberculosis with Pyrazinamide
Trial: NCT00118378
Drug: Modafinil
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg per day, increasing to 200 mg per day as clinically indicated
Trial: NCT03736187
Drug: Cephalexin
RxNorm normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Giving cephalexin and metronidazole in one group \&cephalexin alone in another group
Trial: NCT00419549
Drug: Glyceryl - trinitrate
RxNorm normalized name: glyceryl trinitrate
DrugBank: Nitrate (DB14049)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal Patch once only
Trial: NCT01221883
Drug: Diazepam
RxNorm normalized name: Diazepam
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose 10mg Diazepam tablet
Trial: NCT02277704
Drug: TNX-102 SL
RxNorm normalized name: TNX-901
DrugBank: TNX-901 (DB05797)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01408563
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/m2/day IV x 6 days
Trial: NCT01408563
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg/m2/day IV x 1 day
Trial: NCT03142516
Drug: Panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab 6 mg/kg will be administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy
Trial: NCT03142516
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan 150 mg/m2 will be administered as IV infusion over 90 min on day 1of first treatment cycle. If tolerance of this first dose is good, it will be scaled to a full dose of 180 mg/m2 starting from the second treatment cycle
Trial: NCT03142516
Drug: Folinic acid
RxNorm normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Folinic acid 200-400 mg/m2 will be administered as IV infusion over 2 hours on day 1
Trial: NCT03142516
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU will be administered IV 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2
Trial: NCT01197417
Drug: Normal Saline Placebo
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (1 ml/kg, max 60 ml), administered every 8 hours for a total of 6 doses
Trial: NCT02560974
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin will be administered as an IV infusion, 130 mg/m\^2 on Day 1 of each 3-week cycle for 8 cycles.
Trial: NCT02516410
Drug: VX-661 plus ivacaftor combination
RxNorm normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02516410
Drug: Ivacaftor
RxNorm normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00996931
Drug: lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2.5 mgs per day orally for 12 weeks
Trial: NCT00953472
Drug: brain natriuretic peptide
RxNorm normalized name: Brain natriuretic peptide
DrugBank: .gamma.-brain natriuretic peptide (DB19026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: start 10 mcg/kg (2 participants), 7 mcg/kg (2 participants), 5 mcg/kg (2 participants) and 2 mcg/kg (2 participants)
Trial: NCT01252719
Drug: Single-Dose IV Oritavancin Diphosphate
RxNorm normalized name: Oritavancin Diphosphate
DrugBank: Oritavancin (DB04911)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oritavancin was administered as a single IV dose.
Trial: NCT01252719
Drug: IV Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous vancomycin was administered for a minimum of 7 days and up to a maximum of 10 days.
Trial: NCT01328236
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: INDUCTION THERAPY: 1.3 mg/m2, IV (in the vein) on day 1， 4， 8， 11 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.~MAINTENANCE THERAPY: 1.3 mg/m2, IV (in the vein) on day 1， 4， 8， 11 of each 28 day cycle. 4 Cycles: interval between every two cycles for 6 months, until progression or unacceptable toxicity develops.
Trial: NCT01328236
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: INDUCTION THERAPY: 40 mg/d, IV (in the vein) on day 1- 4 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.~MAINTENANCE THERAPY: 40 mg/d, IV (in the vein) on day 1- 4 of each 28 day cycle. 4 Cycles: interval between every two cycles for 6 months, until progression or unacceptable toxicity develops.
Trial: NCT03325972
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The drug will be administered with a loading dose of 0.5 mcg/kg given over 20 min followed by an infusion at 0.6 mcg/kg/hr. The infusion will be stopped during closure of the fascia.
Trial: NCT01471899
Drug: Ketorolac Tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 drops each 8 hours for 4 days.
Trial: NCT03874494
Drug: Brexpiprazole
RxNorm normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Brexpiprazole 2-4 mg/day
Trial: NCT03874494
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole 10-20 mg/day
Trial: NCT00418522
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine, label instruction initiation dose (10 units), and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
Trial: NCT01387425
Drug: varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: varenicline at a dose of 1 mg twice a day for 12 week
Trial: NCT02695719
Drug: Lubiprostone
RxNorm normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lubiprostone capsules
Trial: NCT02148913
Drug: Cohort 1: Carfilzomib 15 mg/m2
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 15 mg/m2 on day -2, -1, + 5 and +6
Trial: NCT02148913
Drug: Cohort 2: Carfilzomib 20 mg/m2
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 20 mg/m2 on day -2, -1, + 5 and +6